Boai NKY Medical Holdings Ltd
SZSE:300109

Watchlist Manager
Boai NKY Medical Holdings Ltd Logo
Boai NKY Medical Holdings Ltd
SZSE:300109
Watchlist
Price: 16.81 CNY -2.72% Market Closed
Market Cap: 8.1B CNY
Have any thoughts about
Boai NKY Medical Holdings Ltd?
Write Note

Net Margin
Boai NKY Medical Holdings Ltd

26.8%
Current
24%
Average
4.4%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
26.8%
=
Net Income
399.4m
/
Revenue
1.5B

Net Margin Across Competitors

Country CN
Market Cap 8.2B CNY
Net Margin
27%
Country SA
Market Cap 228.3B SAR
Net Margin
1%
Country ID
Market Cap 43.8B USD
Net Margin
-4%
Country ID
Market Cap 633.7T IDR
Net Margin
-4%
Country US
Market Cap 28B USD
Net Margin
2%
Country UK
Market Cap 23.9B USD
Net Margin
5%
Country CN
Market Cap 106.9B CNY
Net Margin
3%
Country US
Market Cap 14.6B USD
Net Margin
1%
Country KR
Market Cap 20.2T KRW
Net Margin
1%
Country CN
Market Cap 87.1B CNY
Net Margin
1%
Country IN
Market Cap 885.7B INR
Net Margin
16%
No Stocks Found

Boai NKY Medical Holdings Ltd
Glance View

Market Cap
8.2B CNY
Industry
Chemicals

Boai NKY Medical Holdings Ltd., founded in the heartland of innovation in Henan Province, China, traces its roots back to an era when the world was rapidly advancing in medical technologies yet still bustling with unmet needs for specialized medical supplies. The company pioneered its focus on producing medical polymer materials and channeled its expertise into the creation of polyvinyl pyrrolidone (PVP), a versatile substance used in pharmaceuticals, cosmetics, and various medical applications. This single compound laid the foundation for the firm's ascent, offering it the placement in the global market where its robust application spans from being a pharmaceutical binder to a blood plasma substitute. The magic of Boai NKY lies in its ability to marry scientific research with commercial execution, ensuring its products meet stringent international standards, thereby opening doors to markets in over 50 countries. The company generates revenue by leveraging its strong manufacturing capabilities and R&D investments. This ensures a steady stream of innovative products catering to the global health industry. Boai NKY's business model diversifies risk by spreading its expertise across biomedicine, cosmetics, agriculture, and food sectors, creating a symbiotic revenue framework. By maintaining a diverse product portfolio and nurturing strategic partnerships, the company builds resilience against market volatility and economic downturns. Its revenue is bolstered not only by domestic sales but by a prominent international presence supported by a network of subsidiaries and distributors. This global footprint ensures a stable cash flow, while continuous investment in technology and quality assurance sustains Boai NKY at the forefront of the competitive chemical manufacturing landscape.

Intrinsic Value
12.92 CNY
Overvaluation 23%
Intrinsic Value
Price

See Also

Discover More
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
26.8%
=
Net Income
399.4m
/
Revenue
1.5B
What is the Net Margin of Boai NKY Medical Holdings Ltd?

Based on Boai NKY Medical Holdings Ltd's most recent financial statements, the company has Net Margin of 26.8%.